Clo­vis' Rubra­ca wins prostate can­cer ap­proval, but da­ta from ri­val Lyn­parza damp­en com­mer­cial ex­pec­ta­tions

While As­traZeneca and Mer­ck’s mar­ket-lead­ing Lyn­parza seem­ing­ly pipped Clo­vis On­col­o­gy’s ri­val Rubra­ca in help­ing prostate can­cer pa­tients, Rubra­ca has, as ex­pect­ed, made it across the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER